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Abstract
Purpose To investigate the effects of a supported home-based progressive resistance exercise training (RET) programme on
indices of cardiovascular health, muscular strength and health-related quality of life (HR-QoL) in prostate cancer (PCa) patients
after treatment with robot-assisted radical prostatectomy (RARP).
Methods This study was a single-site, two-arm randomised controlled trial, with 40 participants randomised to either
the intervention or control group over a 10-month period. In addition to receiving usual care, the intervention group
completed three weekly RET sessions using resistance bands for 6 months. Participants performed 3 sets of 12–15
repetitions for each exercise, targeting each major muscle group. The control group received usual care only.
Brachial artery flow-mediated dilatation (FMD) was the primary outcome and assessed at baseline, 3 and 6 months.
Secondary outcomes included body weight, body fat, aerobic fitness, strength and blood-borne biomarkers associated
with cardiometabolic risk.
Results There was no significant difference between the groups in FMD at 3 or 6 months. However, there were
improvements in aerobic exercise capacity (P < 0.01) and upper- (P < 0.01) and lower-limb (P = 0.01) strength in
favour of the RET group at 6 months, accompanied by greater weight loss (P = 0.04) and a reduction in body fat
(P = 0.02). Improvements in HRQoL were evident in the RET group at 3 and 6 months via the PCa-specific
component of the FACT-P questionnaire (both P < 0.01). Five adverse events and one serious adverse event were
reported throughout the trial duration.
Conclusion This study demonstrates that home-based RET is an effective and safe mode of exercise that elicits beneficial effects
on aerobic exercise capacity, muscular strength and HR-QoL in men who have undergone RARP.
Trial registration ISRCTN10490647.
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Introduction
Robot-assisted radical prostatectomy (RARP) is an
established minimally invasive treatment for localised
prostate cancer (PCa). Men undergoing RARP are
well-counselled about the common side effects of sur-
gery, including erectile dysfunction and urinary inconti-
nence, which can have a negative impact on confidence,
masculinity and health-related quality of life (HR-QoL)
[4, 5, 34]. Men undergoing surgical treatment for PCa
are often considered to be in good general health, per-
haps due to younger age [26] and fewer comorbidities
[44]. However, recent cross-sectional data suggest that
men treated with RARP an average of 11.7 months
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previously have an approximate one in five chances of
a cardiovascular-related event within the next 10 years
and a similar risk of suffering from clinically important
levels of fatigue [6]. This evidence of elevated cardio-
vascular risk is consistent with data from 100 consecu-
tive men diagnosed with localised PCa which showed
an intermediate to high Framingham risk score in >95%
of the patients [17]. Muscular strength may also be ad-
versely affected by surgery in this population. A recent
small-scale study reported a reduction in upper- and
lower-limb strength, which was accompanied by de-
creases in upper- and lower-limb lean body mass, fol-
lowing radical prostatectomy [43]. This evidence pro-
vides a rationale for developing strategies to improve
indices of cardiovascular health and skeletal muscle
function in men with localised PCa undergoing RARP.
Current guidance recommends that men with PCa partici-
pate in structured exercise programmes to improve their health
and HR-QoL [13, 33]. There is no specific exercise guidance
for men after treatment with RARP, other than recommenda-
tions for cancer patients experiencing urinary incontinence
[25], and this reflects the current lack of evidence for this
PCa sub-population [10]. However, a 6-month programme
of aerobic (walking) exercise was shown to improve indices
of cardiovascular health but not erectile dysfunction after sur-
gical treatment for clinically localised PCa [27]. Furthermore,
a 12-week programme of twice-weekly resistance exercise
training (RET), which included pelvic floor exercise, im-
proved physical function, continence rate and quality of life
versus pelvic floor exercise alone after radical prostatectomy
[37].
RET is considered to be safe, and in addition to
increasing skeletal muscle mass, it has been shown to
be effective for improving indices of cardiovascular
health, symptoms of cancer-related fatigue and HR-
QoL in men with PCa and older adults [7, 16, 34,
35]. The majority of studies examining the effects of
RET in clinical populations and older adults have in-
volved supervised exercise [7]. Because supervised ex-
ercise requires travel to an exercise facility, which can
be costly and time-consuming for patients, it can act as
a barrier to participation. However, a key advantage of
RET is that it is a highly accessible form of exercise
that patients can perform at home following a short
instruction period. Home-based RET can be relatively
low-cost and convenient, particularly for older individ-
uals who may have less confidence to use leisure cen-
tres and gym facilities [45]. Hence, the main aim of this
study was to investigate the effects of a home-based
progressive RET programme (encompassing a short pe-
riod of supervised instruction, followed by remote sup-
port) on indices of cardiovascular health in men with
PCa undergoing RARP and, secondly, to assess the




This two-armed randomised controlled trial was designed
with patient and public involvement. A panel consisting of
28 patients at different stages of treatment (recruited from
PCa clinics and the local PCa support group) and healthcare
professionals helped to formulate the study. Furthermore, a
patient representative was appointed to the Trial
Management Group and was consulted on all aspects of the
study.
Participants and setting
Potentially eligible patients attending outpatient clinics were
approached by the urology team and informed about the
study. A patient letter and information sheet were provided.
Patients keen to participate were contacted by a member of the
research team and screened to ensure they met the inclusion
criteria of a PCa diagnosis, undergone RARP in the previous
8–12 weeks and completed a cardiopulmonary exercise test
(CPET) in the previous 4 months. The study exclusion criteria
were receiving any other cancer treatment, planned surgery
within the next 3 months and participating in another clinical
trial where concurrent participation was deemed inappropriate
by a clinical investigator. Consenting men underwent checks
of resting heart rate and blood pressure and cardiac function
using a 12-lead echocardiogram (ECG). The ECG was con-
ducted at rest and was checked by a medical professional.
Participants with no contraindications to exercise were
allowed to continue into the study.
All patients were recruited from the Freeman Hospital,
Newcastle-upon Tyne. The study received ethical approval
from the NHS Research Ethics Committee South Scotland
and was prospectively registered on the International
Standard Randomised Controlled Trial Number database
(ref: ISRCTN10490647). All participants provided written in-
formed consent before enrolment. The Consolidated
Standards of Reporting Trials (CONSORT) guidelines were
followed to guide the reporting of this study [41].
Randomisation and allocation concealment
Participants were randomised to either RET or usual care, with
both groups receiving standard medical treatment (including
pre- and post-operative care). Participants were randomly
assigned (1:1) using a computer-generated block
randomisation schedule (http://www.randomization.com)
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with a block of size 4. The block size and allocation sequence
were not disclosed to ensure concealment. On completion of
screening and the baseline assessment, the lead researcher
emailed the randomisation administrator who responded
with group allocation (RET or usual care).
Intervention
The intervention group completed three weekly sessions of
RET using resistance bands for 6 months. Participants com-
pleted 3 sets of 12–15 repetitions for each exercise in a circuit
[2]. All participants performed 8–10 exercises which targeted
the major muscle group such as legs (squat, leg press, quick
kicks), abdominals (trunk curl-up, lower abdominal crunch,
side bend), back (bent-over row, reverse flies), chest (chest
press), shoulders (upright row, lateral raise, front raise) and
arms (bicep curl and either elbow extension or elbow kick
back). Exercises were performed with 30–60-s interpolated
rest intervals until 3 sets of each exercise had been performed.
The exercise programme was progressed according to the
American College of Sports Medicine (ACSM) guidelines
and the OMNI-Resistance Exercise Scale (OMNI-RES) [39].
The OMNI-RES is a perceived exertion scale for resistance
exercise that helps to control intensity during strength training
exercises and can be applied to both men and women.
Participants were instructed either to alter the hand/foot posi-
tion on the band to increase resistance or to progress onto the
next level of resistance band once 7–8 was reached on the
OMNI-RES [15]. All participants began on the easiest of the
resistance bands for a minimum of 1 week. This enabled all
participants to understand the movements involved in each
exercise with slow progression of the exercises to help avoid
any injury.
Supervision and remote support for the intervention group
Table 1 describes the level of exercise supervision over the
course of the trial. The aim of the supervised sessions was to
ensure that each participant received individual face-to-face
tuition on the appropriate exercise techniques in a designated
room at the hospital. Thereafter, patients were remotely sup-
ported by weekly telephone calls lasting approximately
10 min until 3 months. Telephone calls were used to discuss
any issues and challenges patients had faced with regard to
adherence, exercises and aches and pains, along with advising
on exercise progression. After the third month, participants
received no further contact with the research team until the
6-month outcome assessment session. An exercise booklet
provided instructions for all exercises included in the RET
programme and was used to record weekly RET activity
levels, including the exercises performed, session duration
and frequency and OMNI-RES score, over the 6 months.
Usual care
The control group received usual care only, comprising an
outpatient follow-up appointment every 3 months and advice
regarding incontinence. They were instructed to continue with
their usual activity levels, but no exercise guidance was pro-
vided. Usual care for both groups was not affected by this trial.
Outcome measures
All outcomes were assessed at baseline (prior to
randomisation) and at 3- and 6-month follow-up. In addition
to the primary and secondary outcomes, participant demo-
graphic characteristics such as age, ethnicity, time since sur-
gery, comorbidities and pre-operative prostate-specific anti-
gen (PSA) level were recorded at baseline.
Primary outcome
Flow-mediated dilatation (FMD) was the primary outcome.
FMD is predictive of future cardiovascular events [46], and
there is evidence that men treated with RARP are at elevated
risk [6, 17]. FMD assesses the ability of the brachial artery to
dilate in response to shear stress to test endothelial function.
Participants laid in the supine position for 5 min prior to the
test. A manual sphygmomanometer was placed distal to the
olecranon process, and a resting measurement of vessel
Table 1 Level of supervision
received by the RET group Week Supervision
1 3 supervised exercise sessions
2 2 supervised sessions and 1 in the home environment (i.e. unsupervised)
3–4 1 supervised session and 2 completed at home
5–12 All exercise sessions were unsupervised, but participants in the intervention group received weekly
telephone contact from a member of the research team [23]
13–24 All sessions were unsupervised with no contact from the research team
N.B. Those who did not take up the invite of supervised sessions were contacted weekly via telephone fromweek
1
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diameter was performed for 1 min before cuff inflation to a
pressure 50 mmHg above systolic blood pressure (SBP).
Occlusion was maintained for 5 min. Recordings were
restarted 30 s before cuff release and continued for a further
3 min thereafter [46]. FMD measurements were completed at
each assessment visit. Measurements of the artery diameter
were taken, along with measures of shear rate. Analysis of
FMD recordings was undertaken using Cardiovascular Suite
software (Quipu v3.4, 2018). Measurements of baseline diam-
eter (mm), maximum diameter (mm), recovery diameter
(mm), baseline shear rate (s−1), maximum shear rate (s−1), area
to maximum and FMD (%) were all recorded.
Secondary outcome measures
Participants arrived fasted for venous blood sample collection
which were analysed for blood lipid, insulin and glucose
levels. Anthropometric variables, associated with cardiometa-
bolic risk, were also assessed in the fasted state, including
body mass index (BMI), waist circumference and skinfold
analysis (triceps, subscapular, biceps, iliac crest, supra-spinal,
abdominal, front thigh, medial calf). Exercises from the senior
fitness test were used to evaluate upper- and lower-limb
strength [40]. Lower-limb strength was assessed using the
chair sit-to-stand test, and upper-limb strength was assessed
using the bicep curl test, requiring men to repeatedly lift an
8 lb. (3.63 kg) weight for 30 s [40].
Submaximal aerobic capacity was assessed using the Bruce
ramp protocol on a motorised treadmill (Life Fitness, Next
Gen 9500 Treadmill, Cambridge, UK) [39]. The exercise test
was terminated when the participant reached 15 on Borg’s 6-
20 Rating of Perceived Exertion Scale [28] or for safety rea-
sons if the participant demonstrated an abnormal response to
exercise (e.g. very high heart rate, chest pain, light
headedness). V̇O2 peak was estimated from the level reached
by the participant and using the ACSM Guidelines for
Exercise Testing and Prescription [39].
Questionnaires were used to assess QoL (EQ-5D-5L [48]
and FACT-P [19]), fatigue (Brief Fatigue Inventory [31]) and
self-reported exercise behaviour (modified Godin Leisure
Time Exercise Questionnaire [3]). All permissions were
sought prior to questionnaire use.
Blinding
Due to the nature of the intervention, participants were not
blinded to group allocation. Assessments at 3 and 6 months
that could be influenced by the researcher (e.g. aerobic capac-
ity) were conducted by a trained research assistant blinded to
group allocation to minimise the risk of bias. Analysis of
blood samples and FMD data were also conducted blindly.
Questionnaires were completed by participants independently
and checked by a researcher for completeness.
Sample size estimation
The trial was powered to detect a 2.2% absolute difference
between groups in FMD at 3 months. Previous studies indi-
cate that this is a clinically meaningful difference in terms of
future cardiometabolic risk [8, 51] and one that is realistic to
expect in a parallel-group study in which one group receive a
3-month structured exercise programme [22]. Assuming a
standard deviation of 2.8% [21], the anticipated effect size
was approximately 0.80. The power calculation indicated that
to observe a difference of this magnitude with 80% power and
5% two-sided significance, a total sample size of 52 partici-
pants was required. Allowing for 15% attrition, we aimed to
recruit 60 participants to the trial, with 30 participants
randomised to each group.
Data analysis and missing data
Normality of distribution for the outcome measures was tested
using the Shapiro Wilks test, and assumptions were tested
prior to analysis. The effect of the intervention was evaluated
using an analysis of covariance (ANCOVA) model, with the
baseline value of the outcome included as the covariate. The
treatment effect (intervention minus control) is presented with
95% confidence intervals (CI). Multiple imputation was used
for missing data prior to an intention-to-treat analysis being
conducted [30]. There were missing data for some variables,
and further details are provided in the supplementary material.
Analyses run on the dataset were pooled according to Rubin’s
(1987) rules. All analyses were conducted using IBM SPSS




ACONSORT diagram illustrating recruitment, randomisation
and completion is presented in the supplementary material. Of
73 eligible participants, 42 men were recruited to the trial and
randomised over a 10-month period from June 2017 to April
2018. Participant demographic information is presented in
Table 2.
Intervention adherence
The RET group completed 8–10 exercises per session, with
each session lasting 20–30 min. Adherence to the RET inter-
vention in the first 3 months was 94.1% ± 10.5% with a mean
of 1.9 ± 3.8 sessions missed. During the first 3 months, one
participant suffered a pulmonary embolism judged to be un-
related to the study, and this patient was unable to complete
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2 weeks of the programme as a consequence. In the first 3
months, the three main reasons for missing RET sessions
were a bad back, common cold and holidays. In months 3–
6, adherence in the RET group decreased slightly to 77.7%
± 29.8%, with an average of 8.0 ± 10.6 sessions missed. The
three main reasons for missing sessions in months 3–6 in-
cluded becoming a father, Christmas celebrations, a rotator
cuff injury and holidays, and three participants did not return
their diaries for analysis.
Primary and secondary outcomes
Baseline data are presented in Tables 3 and 4. There was no
significant difference between the groups for FMD variables
at 3 or 6 months (Table 5). However, the RET group expe-
rienced improvements in many of the secondary outcomes at
the 3- and 6-month follow-ups (Table 5). The adjusted mean
difference in submaximal aerobic exercise stage, time and
estimated V̇O2 peak scores were 7.3 (3.0, 11.6), P < 0.01,
142 s (55, 232), P < 0.01 and 7.8 ml/kg/min (3.2, 12.5), P <
0.01 at 3 months respectively and 6.8 (2.4, 11.1), P < 0.01,
140 s (54, 226), P < 0.01 and 8.5 ml/kg/min (3.8, 13.1), P <
0.01 at 6 months, respectively, in favour of the RET group.
The adjusted mean upper and lower body strength scores
were 3.6 (1.7, 5.5) reps, P < 0.01 and 3.1 (1.0, 5.2) reps,
P < 0.01 at 3 months, respectively, and 4.3 (1.2, 7.3) reps,
P < 0.01 and 3.2 (0.6, 5.9) reps, P = 0.02 at 6 months, re-
spectively, again, in favour of the RET group. In addition,
the adjusted mean difference in body mass, percentage fat and
sum of 8 skinfolds were − 3.1 kg (−6.0, −0.2), P = 0.04,
−1.9% (−3.5, −0.4), P = 0.02 and − 13 mm (−25, −1), P =
0.03 at 6 months, respectively, in favour of the RET group.





Age (years) 64.6±6.2 66.9±6.8
Stature (cm) 176.9±7.8 175.8±6.5
Body mass (kg) 88.0±13.3 87.6±13.9
Body mass index (kg/m2) 28.1±3.5 28.3±4.1
White British n (%) 19 (95%) 22 (100%)
Weeks since surgery 10±1 11±2
Pre-operative PSA (ng/ml) 12.1±10.9 11.9±11.3
Hypertension n (%) 14 (33.3%) 8 (19.0%)
Hypercholesterolemia n (%) 6 (14.3%) 9 (21.4%)
T2DM n (%) 4 (9.5%) 1 (2.4%)
Asthma n (%) 4 (9.5%) 0 (0%)
Atrial fibrillation n (%) 2 (4.8%) 0 (0%)
Arthritis n (%) 0 (0%) 2 (4.8%)
Depression n (%) 0 (0%) 2 (4.8%)
Data are presented as mean ± standard deviation unless stated other-
wise. PSA prostate-specific antigen, T2DM type 2 diabetes mellitus
Table 3 Baseline physiological measures
Outcome Exercise group Usual care
Mean ± SD Mean ± SD
Flow-mediated dilatation
Baseline diameter (mm) 4.8 ± 0.6 4.8 ± 0.5
Max diameter (mm) 5.2 ± 0.9 5.1 ± 0.8
Recovery diameter (mm) 5.0 ± 0.6 5.1 ± 0.4
FMD (%) 6.9 ± 2.4 7.6 ± 2.4
Shear baseline (s−1) 76.8 ± 24.5 80.9 ± 20.8
Shear max (s−1) 390.8 ± 76.0 389.8 ± 143.3
Shear area to max 8558.9 ± 1638.5 8883.6 ± 4413.4
Cardiovascular health
Resting heart rate (bpm) 71.7 ± 12.5 66.8 ± 9.3
SBP (mmHg) 138 ± 17 136 ± 15
DBP (mmHg) 82 ± 13 82 ± 9
QRisk-2 Score (%) 17.0 ± 7.7 18.0 ± 6.8
Anthropometric profile
Body mass (kg) 88.0 ± 13.3 87.6 ± 13.9
Body mass index (kg/m2) 28.1 ± 3.5 28.3 ± 4.1
Waist circumference (cm) 99.6 ± 10.0 103.0 ± 9.7
Waist/hip 1.0 ± 0.1 1.0 ± 0.1
Fat (%) 18.3 ± 4.0 17.9 ± 4.6
Sum of 6 skinfolds (mm) 104 ± 25 101 ± 27
Sum of 8 skinfolds (mm) 136 ± 29 133 ± 35
Blood biomarkers
Glucose (mmol/L) 6.2 ± 1.9 5.4 ± 0.6
Insulin (μU/ml) 34.2 ± 14.7 38.4 ± 21.5
HOMA-IR 2.3 ± 5.4 0.6 ± 0.4
Total Chol (mmol/L) 5.0 ± 1.1 5.0 ± 1.5
HDL (mmol/L) 1.3 ± 0.3 1.3 ± 0.3
LDL (mmol/L) 3.2 ± 0.8 2.8 ± 1.2
Non-HDL (mmol/L) 3.7 ± 1.0 3.8 ± 1.5
Triglycerides (mmol/L) 1.5 ± 0.7 1.4 ± 0.6
Total/HDL (mmol/L) 4.0 ± 0.9 4.0 ± 1.1
Submaximal aerobic exercise
Stage 30.0 ± 11.4 29.8 ± 10.3
Time (secs) 580 ± 229 576 ± 205
Estimated VO2Peak (ml/kg/min) 38.6 ± 13.8 38.7 ± 12.5
Max heart rate (bpm) 143.2 ± 17.3 132.9 ± 17.3
Strength
30-s bicep curl test (reps) 20.0 ± 5.7 19.4 ± 4.2
30-s chair stand test (reps) 17.9 ± 5.1 16.1 ± 5.3
SD standard deviation, FMD flow-mediated dilatation, SBP systolic
blood pressure, DBP diastolic blood pressure, HOMA-IR insulin resis-
tance, Chol cholesterol, HDL high-density lipoprotein cholesterol, LDL
low-density lipoprotein cholesterol, VO2Peak maximal aerobic capacity,
reps repetitions, secs seconds
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However, there were no significant differences between the
groups in resting blood pressure, resting heart rate or blood
biomarkers.
There were no changes in EQ-5D or BFI scores at 3 or 6
months (Table 6). However, there were significant changes in
some aspects of the FACT-P. The adjusted mean difference in
functional well-being, PCa specific and FACT-P Trial
Outcome Index (TOI) were 1.9 (0.3, 3.5), P = 0.02, 2.3 (1.0,
3.7), P < 0.01 and 5.0 (1.9, 9.1), P < 0.01 at 3 months, respec-
tively, and 1.9 (0.01, 3.8), P = 0.04, 3.1 (1.3, 5.0), P < 0.01
and 5.0 (1.8, 8.3), P < 0.01 at 6 months, respectively, in favour
of the RET group. Significant changes were also evident for
moderate-intensity activity at 3 months (22.1 [4.1, 40.0], P =
0.02).
Missing data
Approximately 38% of participants had some missing data
over the 6 months of follow-up for FMD. All participants
who attended follow-up sessions had blood taken; however,
approximately 15% of participants did not have some sample
results returned from the laboratory or the results were incom-
plete. The main reason for missing data points was participant
drop-out.
Adverse events
Five adverse events (hernia, accident resulting in back pain,
abdominal pain, increased fasted insulin level, rotator cuff
injury) and one serious adverse event (pulmonary embolism)
were reported throughout the trial duration. Only the report of
a rotator cuff injury was related to the trial and was the result
of a participant choosing to progress to a more difficult resis-
tance band despite being advised otherwise.
Discussion
This is the first study to explore the health benefits of a pre-
dominantly home-supported progressive RET programme
with remote supervision in PCa patients who have recently
undergone RARP. The study demonstrates that RET can be
implemented safely 8 weeks after RARP and can lead to im-
provements in a range of important health outcomes.
Furthermore, there was a high level of adherence to home-
based RET throughout the whole 6 months of the programme.
The results provide some evidence of improved cardiovas-
cular health in the group allocated to RET. FMDwas used as a
simple, non-invasive measure of arterial endothelial function,
which has been used previously in studies of exercise training
in populationswith elevated cardiovascular disease risk, there-
by providing clinically relevant data regarding objective risk
of CVD [46]. We observed no change in FMD at either the 3-
month or 6-month time point in the patients allocated to the
RET group. However, it is likely that the study was under-
powered to detect changes in FMD, as an a priori power cal-
culation indicated that 52 participants were needed to observe
statistically significant differences in FMD between the
groups. Other studies have reported a change in FMD from
6.2–8.3% to 9.7–11.8% after RET programmes, although the
participants were young (18–35 years old), pre-hypertensive
and healthy young (18 years old) adults, respectively [9, 36].
FMD could be a useful non-invasive technique for detecting
changes in arterial function throughout treatment in PCa pa-
tients at elevated risk of cardiovascular disease, but as our
results were inconclusive, further research is warranted.
This study demonstrated that RET improved aerobic
capacity in men post-RARP. This is an important finding
given that aerobic exercise capacity is known to decline
with increasing age and diagnosed hypertension.
Reductions in V̇O2Peak can exacerbate underlying CV
conditions, impair activities of daily living and increase
Table 4 Baseline questionnaire measures
Outcome Exercise group Usual care
Mean ± SD Mean ± SD
Quality of life
EQ-5D Index Score 0.9 ± 0.1 0.8 ± 0.2
ED-5D VAS 82 ± 13 78 ± 14
FACT-P
Physical WB 25.4 ± 1.8 24.3 ± 2.9
Social WB 23.4 ± 3.5 22.5 ± 3.6
Emotional WB 21.6 ± 2.4 20.8 ± 3.7
Functional WB 21.5 ± 5.2 21.2 ± 5.5
Prostate cancer specific 34.5 ± 3.2 33.3 ± 5.2
FACT-P TOI 81.4 ± 8.7 78.8 ± 11.5
FACT-P Total Score 126.4 ± 12.1 122.2 ± 16.2
FACT-G Total Score 91.9 ± 10.0 88.8 ± 12.1
Fatigue
BFI 1.2 ± 1.2 1.9 ± 1.4
Godin Leisure Time Exercise Questionnaire (modified)
VA frequency (days/week) 0.0 ± 0.0 0.4 ± 1.5
VA duration (mins/session) 0.0 ± 0.0 1.1 ± 3.8
MIA frequency (days/week) 1.8 ± 2.8 1.1 ± 2.0
MIA duration (mins/session) 15.9 ± 27.6 25.7 ± 56.5
LIA frequency (days/week) 4.6 ± 2.2 5.3 ± 2.6
LIA duration (mins/session) 40.0 ± 31.5 59.6 ± 61.4
RET frequency (days/week) 0.4 ± 1.6 0.5 ± 1.6
RET duration (mins/session) 0.5 ± 2.2 2.5 ± 9.7
SD standard deviation, VAS visual analogue scale, WB well-being, TOI
trial outcome index,VA vigorous aerobic activity,MIAmoderate intensity
aerobic activity, LIA low-intensity aerobic activity, RET resistance exer-
cise training
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the risk of depression and functional dependence [14, 47].
Submaximal exercise testing, as employed in this study, is
a means of predicting V̇O2Peak without performing
maximal exercise and may be associated with fewer risks
for clinical populations. This type of testing could allow
clinicians to monitor patient progress and be used as a
Table 5 Cardiometabolic outcome measures
Outcome 3 Months 6 Months
Adjusted mean diff. between groups (95% CI) P Value Adjusted mean diff. between groups (95% CI) P Value
Flow-mediated dilatation
Baseline diameter (mm) −0.1 (−0.4, 0.3) 0.4 −0.1 (−0.4, 0.2) 0.4
Max diameter (mm) −0.04 (−0.4, 0.3) 0.7 −0.3 (−0.7, 0.1) 0.2
Recovery diameter (mm) 0.3 (−0.1, 0.7) 0.3 −0.4 (−0.9, 0.1) 0.09
FMD (%) 0.2 (−0.8, 1.2) 0.7 −1.6 (−4.7, 1.4) 0.2
Shear baseline (s−1) 12.5 (−27.9, 53.0) 0.5 −8.2 (−61.8, 45.4) 0.7
Shear max (s−1) 17.8 (−30.1, 65.7) 0.3 −12.2 (−77.0, 52.5) 0.3
Shear area to max −1874.3 (−412.9, 5161.5) 0.5 −673.1 (−3741.5, 2395.3) 0.9
Cardiovascular health
Resting heart rate (bpm) 10.9 (−5, 6) 0.7 1 (−6, 7) 0.8
SBP (mmHg) −6 (−12, 1) 0.07 −7 (−15, 2) 0.1
DBP (mmHg) −1 (−5, 3) 0.6 1 (−5, 7) 0.7
QRisk-2 Score (%) 0.1 (−2.7, 2.9) 0.9 0.3 (−2.7, 3.2) 0.8
Anthropometric profile
Body mass (kg) −1.4 (−3.6, 0.6) 0.2 −3.1 (−6.0, −0.2) 0.04
Body mass index (kg/m2) −0.4 (−1.1, 0.2) 0.2 −1.0 (−1.9, −0.1) 0.03
Waist circumference (cm) −1.3 (−3.9, 1.3) 0.3 −2.3 (−5.1, 0.5) 0.1
Waist/Hip 0.0 (0.0, 0.0) 0.6 −0.03 (−0.1, 0.006) 0.09
Fat (%) −13.2 (−26.8, 0.4) 0.01 −1.9 (−3.5, −0.4) 0.02
Sum of 6 skinfolds (mm) −2 (−3, 0) 0.05 −8 (−17, 1) 0.07
Sum of 8 skinfolds (mm) −12 (−26, 1) 0.07 −13 (−25, −1) 0.03
Blood biomarkers
Glucose (mmol/L) 0.03 (−1.0, 1.0) 0.9 −0.3 (−1.1, 0.4) 0.4
Insulin (μU/ml) −15.2 (−46.2, 15.9) 0.3 −10.7 (−46.7, 25.2) 0.5
HOMA-IR −0.3 (−1.0, 0.3) 0.3 −0.3 (−0.9, 0.3) 0.3
Total Chol (mmol/L) −0.1 (−0.6, 0.4) 0.6 −0.4 (−0.9, 0.03) 0.07
HDL (mmol/L) −0.04 (−0.5, 0.4) 0.6 0.01 (−0.1, 0.1) 0.08
LDL (mmol/L) −0.2 (−0.8, 0.4) 0.8 −0.3 (−0.7, 0.1) 0.2
Non-HDL (mmol/L) −0.2 (−0.5, 0.003) 0.5 −0.3 (−0.9, 0.2) 0.2
Triglycerides (mmol/L) 0.1 (−0.6, 0.8) 0.7 −0.2 (−0.6, 0.2) 0.4
Total/HDL (mmol/L) 0.01 (−0.5, 0.6) 0.9 −0.2 (−0.7, 0.3) 0.4
Submaximal aerobic exercise
Stage 7.3 (3.0, 11.6) < 0.01 6.8 (2.4, 11.1) < 0.01
Time (secs) 142 (55, 232) < 0.01 140 (54, 226) < 0.01
Estimated VO2Peak (ml/kg/min) 7.8 (3.2, 12.5) < 0.01 8.5 (3.8, 13.1) < 0.01
Max heart rate (bpm) 3.1 (−2.8, 9.1) 0.2 6.8 (−0.8, 14.4) 0.07
Strength
30-s bicep curl test (reps) 3.6 (1.7, 5.5) < 0.01 4.3 (1.2, 7.3) < 0.01
30-s chair stand test (reps) 3.1 (1.0, 5.2) < 0.01 3.2 (0.6, 5.9) 0.01
CI confidence interval, FMD flow-mediated dilatation, SBP systolic blood pressure, DBP diastolic blood pressure, HOMA-IR insulin resistance, Chol
cholesterol, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, VO2Peak maximal aerobic capacity, reps repetitions,
secs seconds. Statistical significance: P0.05
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tool to motivate men in continuing with an exercise
programme.
There were favourable but non-significant reductions in
SBP at the 3- and 6-month follow-up time-points in the RET
group. Approximately 50% of myocardial infarctions and
strokes in the UK are attributed to hypertension, and so
interventions to reduce SBP amongst men treated for PCa
could contribute to a reduction in future cardiovascular
events [11]. Importantly, hypertension was shown to be sig-
nificantly more prevalent in a cohort of 100 consecutive
men diagnosed with localised PCa [17], and CVD has been
identified as one of the leading causes of death in men
following RARP [38, 42]. Our results suggest that RET
could be used as a highly accessible, non-pharmacological
method of reducing arterial blood pressure in men with
localised PCa treated with RARP. The design of RET pro-
gramme used in this study also enables implementation dur-
ing the current COVID-19 pandemic. Home-based
programmes with remote support (via telephone, video-
conferencing, etc.) prevent the need for patients to travel
to exercise venues and allow for social distancing measures
to be heeded. However, further research would be needed to
determine the effectiveness of the initial instruction sessions
if carried out virtually.
Table 6 Questionnaire-based
outcome measures Outcome 3 Months 6 Months









EQ-5D Index Score 0.02 (−0.04, 0.1) 0.6 0.1 (−0.01, 0.1) 0.1
ED-5D VAS 1 (−4, 7) 0.7 −1 (−6, 4) 0.7
FACT-P
Physical WB 0.8 (−0.4, 2.0) 0.2 0.2 (−0.9, 1.3) 0.8
Social WB 1.2 (−0.4, 2.8) 0.1 −2.4 (−8.3, 3.5) 0.4
Emotional WB −0.7 (−1.9, 0.6) 0.3 1.1 (−0.1, 2.3) 0.08
Functional WB 1.9 (0.3, 3.5) 0.02 1.9 (0.01, 3.8) 0.04
Prostate cancer
specific
2.3 (1.0, 3.7) <0.01 3.1 (1.3, 5.0) <0.01
FACT-P TOI 5.0 (1.9, 9.1) <0.01 5.0 (1.8, 8.3) <0.01
FACT-P Total
Score
5.3 (0.7, 9.8) 0.03 4.2 (−1.6, 10.1) 0.2
FACT-G Total
Score
3.1 (−0.8, 7.0) 0.1 0.9 (−4.0, 5.7) 0.7
Fatigue
BFI −0.5 (−1.3, 0.3) 0.3 −0.1 (−0.9, 0.6) 0.7
Godin Leisure Time Exercise Questionnaire (modified)
VA frequency
(days/week)
0.1 (−0.4, 0.7) 0.7 0.4 (−0.1, 0.9) 0.2
VA duration
(mins/session)
−27.2 (−66.3, 11.9) 0.2 −3.2 (−14.2, 7.8) 0.6
MIA frequency
(days/week)
0.2 (−1.2, 1.6) 0.8 0.3 (−0.9, 1.5) 0.6
MIA duration
(mins/session)
22.1 (4.1, 40.0) 0.02 16.9 (−8.1, 42.0) 0.2
LIA frequency
(days/week)
−1.0 (−2.4, 0.4) 0.2 −0.7 (−2.2, 0.8) 0.4
LIA duration
(mins/session)
−10.4 (−33.9, 13.2) 0.4 3.4 (−24.1, 30.9) 0.8
RET frequency
(days/week)
2.6 (1.8, 3.5) <0.01 1.9 (1.0, 2.9) <0.01
RET duration
(mins/session)
27.8 (20.7, 35.0) <0.01 17.4 (10.8, 24.0) <0.01
CI confidence interval, VAS visual analogue scale,WBwell-being, TOI trial outcome index, VA vigorous aerobic
activity, MIA moderate intensity aerobic activity, LIA low-intensity aerobic activity, RET resistance exercise
training. Statistical significance: P<0.05
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Improvements were observed in both upper- and lower-
limbmuscular strength in the RET group compared with usual
care. As the average age of those recruited in this study was
>60 years, this suggests that home-based RET could help to
prevent or ameliorate the age-related loss of skeletal muscle
mass and function (i.e. myopenia, sarcopenia, etc.) [2].
Improvements in upper- and lower-limb strength have previ-
ously been reported in studies of PCa after programmes of
RET [20, 50]. However, aside from these improvements in
skeletal muscle strength and function, there were significant
changes in all body composition variables in favour of the
RET group over 6 months of follow-up, suggesting RET is
beneficial for promoting fat loss in PCa patients undergoing
RARP, and this is consistent with data from other populations
[49]. The effects of RET on body fat stores are potentially
attributable to an increase in total daily energy expenditure
on exercising days and as the involved skeletal muscles adapt
to training, as some studies have shown increases in basal
metabolic rates and fat oxidation following RET [1, 29].
Finally, the results of this study suggest that RET can im-
prove patient-reported functional well-being and HR-QoL.
This is noteworthy, given that studies have recently reported
mental health issues and reduce HR-QoL in the years imme-
diately after PCa diagnosis [12]. The significant difference
between the two groups observed in this study suggests that
RET is more beneficial than usual care [18] and could there-
fore have clinical implications regarding the advice and rec-
ommendations clinicians make for patients at this stage of
their recovery. Participants reported improved PCa specific
side effects via the FACT-P questionnaire. Therefore, it can
be concluded that RET did not exert any negative effects on
incontinence or erectile dysfunction and that participants in
the RET group reported a perceived improvements in these
commonly reported side effects of RARP. As a result, men
could be counselled by healthcare professionals to not be con-
cerned about the effect RET may have on their functional
status especially with the programme being conducted in the
home environment. RET did not appear to benefit fatigue but
did not worsen reported fatigue levels. The lack of change
could be due to the low fatigue levels reported by participants
at baseline, and the study was probably underpowered to de-
tect any small, but potentially important, difference in the
fatigue outcome. However, other studies have reported that
exercise has reduced the levels of fatigue in other cancer pop-
ulations [32].
Limitations
This study has a number of important limitations. Firstly, the
study was underpowered to detect changes in the primary
outcome, though significant beneficial effects were evident
for many of the secondary outcomes (e.g. body weight, body
fat, aerobic fitness, strength, FACT-P). Secondly, although a
widely adopted multiple imputation technique was used to
account for missing data points [24], missing data contributes
to a loss of statistical power and potential bias. Adding to this,
some participants were not fully compliant, with some exer-
cise diaries lost or not returned for analysis. Thirdly, it is
possible that due to patients being aware of their participation
in an exercise trial, they undertook more daily exercise (in
addition to RET), and this may have accounted for the ob-
served increase in moderate-intensity physical activity and
improvement in aerobic exercise capacity in this group.
Fourthly, diet was not accounted for and may have improved
due to participation in the trial, potentially leading to
favourable reductions in body/fat mass. Finally, it is unclear
how the intervention specifically impacted common side ef-
fects of RARP, including erectile dysfunction and urinary in-
continence. Future research should expand on these prelimi-
nary findings and explore the impact of RET on key health
outcomes in a larger multi-centre randomised controlled trial.
Conclusions
This study highlights that RET is a safe, effective and feasible
mode of exercise that elicits cardiometabolic health benefits in
men who have undergone RARP. RET is an accessible form
of exercise for PCa patients recovering fromRARP and, when
provided with appropriate information, demonstrates good ad-
herence to the programme and reports few trial-related adverse
events. Therefore, clinicians should consider discussing the
benefits of exercise, including RET, to patients in the weeks
following RARP.
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